1 / 24

TOC - Global Molecular Oncology Diagnostics Market

The global molecular oncology diagnostics market was valued at $3,620.6 million in 2021 and is anticipated to reach $12,130.5 million by 2032, witnessing a CAGR of 11.43% during the forecast period 2022-2032.<br>

bisreports
Télécharger la présentation

TOC - Global Molecular Oncology Diagnostics Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Molecular Oncology Diagnostics Market - A Global and Regional Analysis Table of Content GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET Focus on Product, Technology, Application, Cancer Type, End User, and Region Analysis and Forecast: 2022-2032 November 2022 1 All rights reserved at BIS Research Inc.

  2. BIS Research is a leading market intelligence and technology research company. BIS Research publishes in- depth market intelligence reports focusing on the market estimations, technology analysis, emerging high- growth applications, deeply segmented granular country-level market data and other important market parameters useful in the strategic decision making for senior management. BIS Research provides multi-client reports, company profiles, databases, and custom research services. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET Copyright © 2022 BIS Research Inc. All Rights Reserved. This document contains highly confidential information and is the sole property of BIS Research. Disclosing, copying, circulating, quoting, or otherwise reproducing any or all contents of this document is strictly prohibited. Access to this information is provided exclusively for the benefit of the people or organization concerned. It may not be accessed by or offered whether for sale or otherwise to any third party. 2 All rights reserved at BIS Research Inc.

  3. Table of Content Executive Summary .......................................................................... 24 1.Market ....................................................................................... 32 1.1 Product Definition ............................................................................................ 33 1.2 Inclusion and Exclusion .................................................................................. 34 1.3 Scope of the Study .......................................................................................... 34 1.4 Key Questions Answered in the Report......................................................... 35 2.Research Methodology .............................................................. 37 2.1 Global Methodology .................................................................................................... 37 Molecular Oncology Diagnostics Market: Research 2.2 Primary Data Sources ..................................................................................... 37 2.3 Secondary Data Sources ................................................................................ 38 2.4 Market Estimation Model ................................................................................. 39 2.5 Criteria for Company Profiling ........................................................................ 41 3.Global Molecular Oncology Diagnostics Market: Overview ......... 42 3.1 Market Overview .............................................................................................. 42 3.1.1 Evolution of Molecular Cancer Diagnostics and Current Status ..................... 42 3.2 Global Molecular Oncology Diagnostics Market Size and Forecast (2021-2032) ....................................................................................................... 43 GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET 3.3 Global Incidence and Prevalence of Cancer (by Type) ................................ 44 3.3.1 North America ...................................................................................................... 44 3.3.1.1 Solid Tumor .................................................................................................... 44 3.3.1.2 Hematological Malignancy .............................................................................. 45 3.3.2 Europe ................................................................................................................... 46 3.3.2.1 Solid Tumor .................................................................................................... 46 3.3.2.2 Hematological Malignancy .............................................................................. 47 3.3.3 Asia-Pacific ........................................................................................................... 48 3.3.3.1 Solid Tumor .................................................................................................... 48 3.3.3.2 Hematological Malignancy .............................................................................. 48 3.4 Impact of COVID-19 on the Molecular Oncology Diagnostics Market ......... 49 3 All rights reserved at BIS Research Inc.

  4. 3.4.1 Impact on Market Size ......................................................................................... 50 3.5 Liquid Biopsy-Based Cancer Molecular Diagnostics ................................... 51 3.6 Laboratory Developed Test (LDT) Vs. In Vitro Diagnostic (IVD) .................. 52 Role of Companion Diagnostics in the Molecular Oncology Diagnostics Market .......................................................................................... 52 4.Global Molecular Oncology Diagnostics Market: Industry Analysis ..................................................................................... 55 3.7 4.1 Legal Requirements and Framework in the U.S. ........................................... 56 4.1.1 FDA Regulation .................................................................................................... 56 4.1.2 CMS Regulation (Reimbursement Scenario) ..................................................... 57 4.2 Legal Requirements and Framework in Europe ............................................ 58 4.3 Legal Requirements and Framework in Asia-Pacific .................................... 59 4.3.1 China ..................................................................................................................... 59 4.3.2 Japan ..................................................................................................................... 60 5.Market Dynamics ....................................................................... 62 5.1 Overview ........................................................................................................... 63 5.1 Impact Analysis ............................................................................................... 63 5.2 Growth Drivers ................................................................................................. 65 5.2.1 Rising Incidence of Cancer Cases ..................................................................... 65 GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET 5.2.2 Launch of Innovative Products in Molecular Oncology Diagnostics Ecosystem ............................................................................................................ 67 5.2.3 Growth in Biomarker identification and Transformations in Molecular Techniques ........................................................................................................... 67 5.3 Growth Restraints ............................................................................................ 69 5.3.1 Lack of Qualified Professionals .......................................................................... 69 5.3.2 Opaque Regulatory Framework Delaying the Approval of New Molecular Diagnostic Tests .................................................................................................. 69 5.3.3 High Cost of Equipment Hindering the Adoption Rate..................................... 70 5.4 Growth Opportunities ...................................................................................... 71 5.4.1 Partnerships Stakeholders ......................................................................................................... 71 and Collaborations between Various Healthcare 4 All rights reserved at BIS Research Inc.

  5. 5.4.2 Upsurge of Next-Generation Ultrasensitive Molecular Diagnostics ................ 72 6.Competitive Landscape ............................................................. 74 6.1 Mergers and Acquisitions ............................................................................... 76 6.2 Synergistic Activities ...................................................................................... 77 6.3 Product Launch and Approval Activities ....................................................... 78 6.4 Expansion, Insurance, and Other Key Developments .................................. 79 6.5 Market-Share Analysis .................................................................................... 79 Growth-Share Analysis ................................................................................... 81 7.Global Molecular Oncology Diagnostics Market (by Product), $Million, 2021-2032 .................................................................... 83 6.6 7.1 Overview ........................................................................................................... 84 7.2 Kits and Assays ............................................................................................... 85 7.3 Instruments ...................................................................................................... 87 Software ........................................................................................................... 88 8.Global Molecular Oncology Technology), $Million, 2021-2032 ............................................... 90 7.4 Diagnostics Market (by 8.1 Overview ........................................................................................................... 91 8.2 Polymerase Chain Reaction (PCR) ................................................................. 93 8.3 Next-Generation Sequencing (NGS) .............................................................. 94 GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET 8.4 Immunohistochemistry (IHC) .......................................................................... 95 8.5 Fluorescence In-Situ Hybridization (FISH) .................................................... 96 8.6 Flow Cytometry ................................................................................................ 97 8.7 Other Technologies ......................................................................................... 98 9.Global Application), $Million, 2021-2032 ............................................... 99 Molecular Oncology Diagnostics Market (by 9.1 Overview ......................................................................................................... 100 9.2 Clinical Diagnostic ......................................................................................... 101 Research Use ................................................................................................. 102 10.Global Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032 ....................................................... 103 9.3 10.1Overview ......................................................................................................... 104 5 All rights reserved at BIS Research Inc.

  6. 10.1.1 Solid Tumor ........................................................................................................ 105 10.1.1.1 Breast Cancer ............................................................................................... 106 10.1.1.2 Lung Cancer ................................................................................................. 107 10.1.1.3 Colorectal Cancer ......................................................................................... 108 10.1.1.4 Prostate Cancer ............................................................................................ 109 10.1.1.5 Ovarian Cancer ............................................................................................. 110 10.1.1.6 Other Solid Tumors ....................................................................................... 111 10.1.2 Hematological Malignancy ................................................................................ 112 10.1.2.1 Lymphoma .................................................................................................... 113 10.1.2.2 Leukemia ...................................................................................................... 114 10.1.2.3 Multiple Myeloma .......................................................................................... 115 10.1.2.4 Other Hematological Malignancies ............................................................... 116 11.Global Molecular Oncology Diagnostics Market (by End User), $Million, 2021-2032 .................................................................. 118 11.1Overview ......................................................................................................... 119 11.2Hospitals and Diagnostic Centers ................................................................ 120 11.3Reference Laboratories ................................................................................. 121 11.4Pharmaceutical and Biotechnology Companies ......................................... 122 11.5Academic and Research Institutes ...................... Error! Bookmark not defined. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET 12.Region ..................................................................................... 124 12.1Overview ......................................................................................................... 125 12.2North America ................................................................................................ 127 12.2.1 U.S. ...................................................................................................................... 131 12.2.2 Canada ................................................................................................................ 134 12.3Europe ............................................................................................................ 138 12.3.1 Germany .............................................................................................................. 141 12.3.2 France ................................................................................................................. 145 12.3.3 U.K. ...................................................................................................................... 149 12.3.4 Italy ...................................................................................................................... 152 12.3.5 Spain ................................................................................................................... 155 6 All rights reserved at BIS Research Inc.

  7. 12.3.6 Rest-of-Europe ................................................................................................... 159 12.4Asia-Pacific .................................................................................................... 162 12.4.1 China ................................................................................................................... 165 12.4.2 India ..................................................................................................................... 169 12.4.3 Japan ................................................................................................................... 172 12.4.4 South Korea ........................................................................................................ 176 12.4.5 Australia .............................................................................................................. 179 12.4.6 Rest-of-Asia-Pacific ........................................................................................... 183 12.5Rest-of-the-World (RoW) ............................................................................... 187 13.Company Profiles ..................................................................... 189 13.1Agilent Technologies, Inc. ............................................................................ 191 13.1.1 Company Overview ............................................................................................ 191 13.1.2 Role of Agilent Technologies, Inc. in the Global Molecular Oncology Diagnostics Market ............................................................................................ 191 13.1.3 Key Competitors of the Company .................................................................... 191 13.1.4 Business Strategies ........................................................................................... 192 13.1.4.1 Merger and Acquisition ................................................................................. 192 13.1.4.2 Product Launch/Approval ............................................................................. 192 13.1.4.3 Expansion ..................................................................................................... 192 GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET 13.1.5 Financials ............................................................................................................ 193 13.1.6 Analyst Perspective ........................................................................................... 195 13.2Abbott. ............................................................................................................ 196 13.2.1 Company Overview ............................................................................................ 196 13.2.2 Role of Abbott. in the Global Molecular Oncology Diagnostics Market ....... 196 13.2.3 Key Competitors of the Company .................................................................... 196 13.2.4 Key Customers of the Company ....................................................................... 197 13.2.5 Financials ............................................................................................................ 197 13.2.6 Key Insights about the Financial Health of the Company .............................. 199 13.2.7 Analyst Perspective ........................................................................................... 200 13.3Biocartis NV ................................................................................................... 201 7 All rights reserved at BIS Research Inc.

  8. 13.3.1 Company Overview ............................................................................................ 201 13.3.2 Role of Biocartis NV in the Global Molecular Oncology Diagnostics Market .................................................................................................................. 201 13.3.3 Key Competitors of the Company .................................................................... 201 13.3.4 Corporate Strategies .......................................................................................... 201 13.3.4.1 Synergistic Activities ..................................................................................... 201 13.3.5 Business Strategies ........................................................................................... 202 13.3.5.1 Product Launch/Approval ............................................................................. 202 13.3.6 Financials ............................................................................................................ 203 13.3.7 Analyst Perspective ........................................................................................... 203 13.4Bio-Rad Laboratories, Inc. ............................................................................ 204 13.4.1 Company Overview ............................................................................................ 204 13.4.2 Role of Bio-Rad Laboratories, Inc. in the Global Molecular Oncology Diagnostics Market ............................................................................................ 204 13.4.3 Key Competitors of the Company .................................................................... 204 13.4.4 Corporate Strategies .......................................................................................... 205 13.4.4.1 Synergistic Activities ..................................................................................... 205 13.4.5 Business Strategies ........................................................................................... 205 13.4.5.1 Merger and Acquisition ................................................................................. 205 GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET 13.4.5.2 Product Launch/Approval ............................................................................. 205 13.4.6 Financials ............................................................................................................ 206 13.4.7 Analyst Perspective ........................................................................................... 208 13.5F. Hoffmann-La Roche Ltd. ........................................................................... 209 13.5.1 Company Overview ............................................................................................ 209 13.5.2 Role of F. Hoffmann-La Roche Ltd. in the Global Molecular Oncology Diagnostics Market ............................................................................................ 209 13.5.3 Key Competitors of the Company .................................................................... 209 13.5.4 Corporate Strategies .......................................................................................... 210 13.5.4.1 Synergistic Activities ..................................................................................... 210 13.5.5 Business Strategies ........................................................................................... 210 8 All rights reserved at BIS Research Inc.

  9. 13.5.5.1 Product Launch/Approval ............................................................................. 210 13.5.5.2 Expansion ..................................................................................................... 210 13.5.6 Financials ............................................................................................................ 211 13.5.7 Analyst Perspective ........................................................................................... 214 13.6QIAGEN N.V. ................................................................................................... 215 13.6.1 Company Overview ............................................................................................ 215 13.6.2 Role of QIAGEN N.V. in the Global Molecular Oncology Diagnostics Market .................................................................................................................. 215 13.6.3 Key Competitors of the Company .................................................................... 215 13.6.4 Key Customers of the Company ....................................................................... 216 13.6.5 Corporate Strategies .......................................................................................... 216 13.6.5.1 Synergistic Activities ..................................................................................... 216 13.6.6 Business Strategies ........................................................................................... 217 13.6.6.1 Merger and Acquisition ................................................................................. 217 13.6.6.2 Product Launch/Approval ............................................................................. 217 13.6.7 Financials ............................................................................................................ 217 13.6.8 Analyst Perspective ........................................................................................... 220 13.7Thermo Fisher Scientific, Inc. ....................................................................... 221 13.7.1 Company Overview ............................................................................................ 221 GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET 13.7.2 Role of Thermo Fisher Scientific, Inc. in the Global Molecular Oncology Diagnostics Market ............................................................................................ 221 13.7.3 Key Competitors of the Company .................................................................... 221 13.7.4 Corporate Strategies .......................................................................................... 222 13.7.4.1 Synergistic Activities ..................................................................................... 222 13.7.5 Business Strategies ........................................................................................... 222 13.7.5.1 Product Launch/Approval ............................................................................. 222 13.7.5.2 Expansion ..................................................................................................... 222 13.7.6 Financials ............................................................................................................ 223 13.7.7 Analyst Perspective ........................................................................................... 226 13.8Danaher. ......................................................................................................... 227 9 All rights reserved at BIS Research Inc.

  10. 13.8.1 Company Overview ............................................................................................ 227 13.8.2 Role of Danaher. in the Global Molecular Oncology Diagnostics Market..... 227 13.8.3 Key Competitors of the Company .................................................................... 228 13.8.4 Corporate Strategies .......................................................................................... 228 13.8.4.1 Synergistic Activities ..................................................................................... 228 13.8.5 Financials ............................................................................................................ 229 13.8.6 Key Insights about the Financial Health of the Company .............................. 231 13.8.7 Analyst Perspective ........................................................................................... 231 13.9Guardant Health ............................................................................................. 232 13.9.1 Company Overview ............................................................................................ 232 13.9.2 Role of Guardant Health in the Global Molecular Oncology Diagnostics Market .................................................................................................................. 232 13.9.3 Key Competitors of the Company .................................................................... 232 13.9.4 Key Customers of the Company ....................................................................... 233 13.9.5 Corporate Strategies .......................................................................................... 233 13.9.5.1 Synergistic Activities ..................................................................................... 233 13.9.6 Business Strategies ........................................................................................... 233 13.9.6.1 Product Launch/Approval ............................................................................. 233 13.9.7 Financials ............................................................................................................ 234 GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET 13.9.8 Key Insights about the Financial Health of the Company .............................. 236 13.9.9 Analyst Perspective ........................................................................................... 236 13.10HTG Molecular Diagnostics, Inc. .................................................................. 238 13.10.1Company Overview ............................................................................................ 238 13.10.2Role of HTG Molecular Diagnostics, Inc. in the Global Molecular Oncology Diagnostics Market ........................................................................... 238 13.10.3Key Competitors of the Company .................................................................... 238 13.10.4Business Strategies ........................................................................................... 239 13.10.4.1 Product Launch/Approval ............................................................................. 239 13.10.5Financials ............................................................................................................ 240 13.10.6Key Insights about the Financial Health of the Company .............................. 241 10 All rights reserved at BIS Research Inc.

  11. 13.10.7Analyst Perspective ........................................................................................... 242 13.11Illumina, Inc. ................................................................................................... 243 13.11.1Company Overview ............................................................................................ 243 13.11.2Role of Illumina, Inc. in the Global Molecular Oncology Diagnostics Market .................................................................................................................. 243 13.11.3Key Competitors of the Company .................................................................... 243 13.11.4Corporate Strategies .......................................................................................... 244 13.11.4.1 Synergistic Activities ..................................................................................... 244 13.11.5Business Strategies ........................................................................................... 244 13.11.5.1 Merger and Acquisition ................................................................................. 244 13.11.6Financials ............................................................................................................ 245 13.11.7Key Insights about the Financial Health of the Company .............................. 247 13.11.8Analyst Perspective ........................................................................................... 247 13.12Invivoscribe, Inc. ............................................................................................ 249 13.12.1Company Overview ............................................................................................ 249 13.12.2Role of Invivoscribe, Inc. in the Global Molecular Oncology Diagnostics Market .................................................................................................................. 249 13.12.3Key Competitors of the Company .................................................................... 249 13.12.4Corporate Strategies .......................................................................................... 249 GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET 13.12.4.1 Synergistic Activities ..................................................................................... 249 13.12.5Business Strategies ........................................................................................... 250 13.12.5.1 Product Launch/Approval ............................................................................. 250 13.12.6Analyst Perspective ........................................................................................... 250 13.13Myriad Genetics, Inc. ..................................................................................... 252 13.13.1Company Overview ............................................................................................ 252 13.13.2Role of Myriad Genetics, Inc. in the Global Molecular Oncology Diagnostics Market ............................................................................................ 252 13.13.3Key Competitors of the Company .................................................................... 252 13.13.4Corporate Strategies .......................................................................................... 252 13.13.4.1 Synergistic Activities ..................................................................................... 252 11 All rights reserved at BIS Research Inc.

  12. 13.13.5Business Strategies ........................................................................................... 253 13.13.5.1 Product Launch/Approval ............................................................................. 253 13.13.6Financials ............................................................................................................ 254 13.13.7Key Insights about the Financial Health of the Company .............................. 255 13.13.8Analyst Perspective ........................................................................................... 256 13.14Sysmex Corporation ...................................................................................... 257 13.14.1Company Overview ............................................................................................ 257 13.14.2Role of Sysmex Corporation in the Global Molecular Oncology Diagnostics Market ............................................................................................ 257 13.14.3Key Competitors of the Company .................................................................... 257 13.14.4Corporate Strategies .......................................................................................... 257 13.14.4.1 Synergistic Activities ..................................................................................... 257 13.14.5Business Strategies ........................................................................................... 258 13.14.5.1 Product Launch/Approval ............................................................................. 258 13.14.5.2 Expansion ..................................................................................................... 258 13.14.6Financials ............................................................................................................ 259 13.14.7Key Insights about the Financial Health of the Company .............................. 260 13.14.8Analyst Perspective ........................................................................................... 260 GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET 12 All rights reserved at BIS Research Inc.

  13. List of Figures Figure 1: Annual NIH Funding in Human Genomics Research, $Billion, FY2013-FY2019 Figure 2: Global Molecular Oncology Diagnostics Market, $Million, 2021-2032 Figure 3: Global Molecular Oncology Diagnostics Market, Dynamics Figure 4: Share of Key Market Strategies and Developments, January 2019-October 2022 Figure 5: Global Molecular Oncology Diagnostics Market (by Product), $Million, 2021 Vs. 2032 Figure 6: Global Molecular Oncology Diagnostics Market (by Technology), $Million, 2021 Vs. 2032 Figure 7: Global Molecular Oncology Diagnostics Market (by Application), $Million, 2021 Vs. 2032 Figure 8: Global Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021 Vs. 2032 Figure 9: Global Molecular Oncology Diagnostics Market (by End User), $Million, 2021 Vs. 2032 Figure 10:Global Molecular Diagnostics Market (by Region), $Million, 2021 Vs. 2032 Figure 11:Role of Diagnostics in Healthcare Figure 12:Global Molecular Oncology Diagnostics Market Segments Figure 13:Global Molecular Oncology Diagnostics Market: Methodology Figure 14:Primary Research Methodology Figure 15:Bottom-Up Approach (Segment-Wise Analysis) Figure 16:Top-Down Approach (Segment-Wise Analysis) Figure 17:Global Molecular Oncology Diagnostics Market, $Million, 2021-2032 Figure 18:Solid Tumor Prevalence and Incidence Data in Europe, 2020 GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET Figure 19:Hematological Malignancy Prevalence and Incidence Data in North America, 2020 Figure 20:Solid Tumor Prevalence and Incidence Data in Europe, 2020 Figure 21:Hematological Malignancy Prevalence and Incidence Data in Europe, 2020 Figure 22:Solid Tumor Prevalence and Incidence Data in Asia-Pacific, 2020 Figure 23:Hematological Malignancy Prevalence and Incidence Data in Asia-Pacific, 2020 Figure 24:Global Molecular Oncology Diagnostics Market, $Million, 2019-2021 Figure 25:Prominent FDA-Approved CDx Tests for Molecular Oncology Diagnostics Figure 26:FDA Guidelines for CDx Approval Figure 27:Criteria for CMS Coverage/Reimbursement Figure 28:Europe In Vitro Diagnostic Devices Regulation Regulatory Process Figure 29:Workflow for Medical Device Regulations Figure 30:Global Molecular Diagnostics Market: Market Dynamics Figure 31:Likert Scale 13 All rights reserved at BIS Research Inc.

  14. Figure 32:Impact Analysis of Market Drivers and Challenges on the Global Molecular Oncology Diagnostics Market Figure 33:Global Distribution of Cases and Deaths (by Cancer Type), 2020 Figure 34:Global Incidence for Cancer Types (2017-2019) Figure 35:Product Upgradations and Technological Advancements, 2019-2022 Figure 36:Synergistic Activities, 2019-2021 Figure 37:Share of Key Developments and Strategies, January 2019-October 2022 Figure 38:Share of Mergers and Acquisitions (by Company), January 2019-October 2022 Figure 39:Share of Synergistic Activities (by Company), January 2019-October 2022 Figure 40:Share of Product Launch and Approval Activities (by Company), January 2019-October 2022 Figure 41:Share of Expansion, Insurance, and Other Key Developments (by Company), January 2019- October 2022 Figure 42:Market-Share Analysis for the Global Molecular Oncology Diagnostics Market, $Million, 2021 Figure 43:Growth-Share Analysis of Global Molecular Oncology Diagnostics Market (by Technology), 2021-2032 Figure 44:Global Molecular Oncology Diagnostics Market (by Product) Figure 45:Share of Global Molecular Oncology Diagnostics Market (by Product), $Million, 2021 and 2032 Figure 46:Global Molecular Oncology Diagnostics Market (Kits and Assays), $Million, 2021-2032 Figure 47:Global Molecular Oncology Diagnostics Market (Instruments), $Million, 2021-2032 Figure 48:Global Molecular Oncology Diagnostics Market (Software), $Million, 2021-2032 GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET Figure 49:Global Molecular Oncology Diagnostics Market (by Technology) Figure 50:Share of Global Molecular Oncology Diagnostics Market (by Technology), $Million, 2021 and 2032 Figure 51:Global Molecular Oncology Diagnostics Market (Polymerase Chain Reaction), $Million, 2021- 2032 Figure 52:Global Molecular Oncology Diagnostics Market (Next-Generation Sequencing), $Million, 2021- 2032 Figure 53:Global Molecular Oncology Diagnostics Market (Immunohistochemistry), $Million, 2021-2032 Figure 54:Global Molecular Oncology Diagnostics Market (Fluorescence In-Situ Hybridization), $Million, 2021-2032 Figure 55:Global Molecular Oncology Diagnostics Market (Flow Cytometry), $Million, 2021-2032 Figure 56:Global Molecular Oncology Diagnostics Market (Other Technologies), $Million, 2021-2032 Figure 57:Share of Global Molecular Oncology Diagnostics Market (by Application), $Million, 2021 and 2032 14 All rights reserved at BIS Research Inc.

  15. Figure 58:Global Molecular Oncology Diagnostics Market (Clinical Diagnostic), $Million, 2021-2032 Figure 59:Global Molecular Oncology Diagnostics Market (Research Use), $Million, 2021-2032 Figure 60:Global Molecular Oncology Diagnostics Market (by Cancer Type) Figure 61:Share of Global Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021 and 2032 Figure 62:Global Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021 and 2032 Figure 63:Global Molecular Oncology Diagnostics Market (Breast Cancer), $Million, 2021-2032 Figure 64:Global Molecular Oncology Diagnostics Market (Lung Cancer), $Million, 2021-2032 Figure 65:Global Molecular Oncology Diagnostics Market (Colorectal Cancer), $Million, 2021-2032 Figure 66:Global Molecular Oncology Diagnostics Market (Prostate Cancer), $Million, 2021-2032 Figure 67:Global Molecular Oncology Diagnostics Market (Ovarian Cancer), $Million, 2021-2032 Figure 68:Global Molecular Oncology Diagnostics Market (Other Solid Tumors), $Million, 2021-2032 Figure 69:Global Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021 and 2032 Figure 70:Global Molecular Oncology Diagnostics Market (Lymphoma), $Million, 2021-2032 Figure 71:Global Molecular Oncology Diagnostics Market (Leukemia), $Million, 2021-2032 Figure 72:Global Molecular Oncology Diagnostics Market (Multiple Myeloma), $Million, 2021-2032 Figure 73:Global Molecular Oncology Diagnostics Market (Other Hematological Malignancies), $Million, 2021-2032 Figure 74:Share of Global Molecular Oncology Diagnostics Market (by End User), $Million, 2021 and 2032 GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET Figure 75:Global Molecular Oncology Diagnostics Market (Hospitals and Diagnostic Centers), $Million, 2021-2032 Figure 76:Global Molecular Oncology Diagnostics Market (Reference Laboratories), $Million, 2021-2032 Figure 77:Global Molecular Oncology Diagnostics Market (Pharmaceutical and Biotechnology Companies), $Million, 2021-2032 Figure 78:Global Molecular Oncology Diagnostics Market (Academic and Research Institutes), $Million, 2021-2032 Figure 79:Global Molecular Oncology Diagnostics Market Snapshot (by Region), $Million, 2021-2032 Figure 80:Global Molecular Oncology Diagnostics Market (by Region), $Million, 2021-2032 Figure 81:North America Molecular Oncology Diagnostics Market, $Million, 2021-2032 Figure 82:North America: Market Dynamics Figure 83:North America Molecular Oncology Diagnostics Market (by Country), $Million, 2021 and 2032 Figure 84:U.S. Molecular Oncology Diagnostics Market, $Million, 2021-2032 15 All rights reserved at BIS Research Inc.

  16. Figure 85:U.S. Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032 Figure 86:U.S. Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032 Figure 87:U.S. Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021- 2032 Figure 88:Canada Molecular Oncology Diagnostics Market, $Million, 2021-2032 Figure 89:Canada Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032 Figure 90:Canada Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032 Figure 91:Canada Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-2032 Figure 92:Europe Molecular Oncology Diagnostics Market, $Million, 2021-2032 Figure 93:Europe: Market Dynamics Figure 94:Europe Molecular Oncology Diagnostics Market (by Country), $Million, 2021 and 2032 Figure 95:Germany Molecular Oncology Diagnostics Market, $Million, 2021-2032 Figure 96:Germany Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032 Figure 97:Germany Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032 Figure 98:Germany Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-2032 Figure 99:France Molecular Oncology Diagnostics Market, $Million, 2021-2032 Figure 100:France Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032 Figure 101:France Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032 GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET Figure 102:France Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021- 2032 Figure 103:U.K. Molecular Oncology Diagnostics Market, $Million, 2021-2032 Figure 104:U.K. Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032 Figure 105:U.K. Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032 Figure 106:U.K. Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021- 2032 Figure 107:Italy Molecular Oncology Diagnostics Market, $Million, 2021-2032 Figure 108:Italy Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032 Figure 109:Italy Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032 Figure 110:Italy Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021- 2032 Figure 111:Spain Molecular Oncology Diagnostics Market, $Million, 2021-2032 16 All rights reserved at BIS Research Inc.

  17. Figure 112:Spain Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032 Figure 113:Spain Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032 Figure 114:Spain Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021- 2032 Figure 115:Rest-of-Europe Molecular Oncology Diagnostics Market, $Million, 2021-2032 Figure 116:Rest-of-Europe Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032 Figure 117:Rest-of-Europe Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032 Figure 118:Rest-of-Europe Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-2032 Figure 119:Asia-Pacific Molecular Oncology Diagnostics Market (by Region), $Million, 2021-2032 Figure 120:Asia-Pacific: Market Dynamics Figure 121:Asia-Pacific Molecular Oncology Diagnostics Market (by Country), $Million, 2021 and 2032 Figure 122:China Molecular Oncology Diagnostics Market, $Million, 2021-2032 Figure 123:China Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032 Figure 124:China Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032 Figure 125:China Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021- 2032 Figure 126:India Molecular Oncology Diagnostics Market, $Million, 2021-2032 Figure 127:India Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032 Figure 128:India Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032 GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET Figure 129:India Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021- 2032 Figure 130:Japan Molecular Oncology Diagnostics Market, $Million, 2021-2032 Figure 131:Japan Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032 Figure 132:Japan Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032 Figure 133:Japan Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021- 2032 Figure 134:South Korea Molecular Oncology Diagnostics Market, $Million, 2021-2032 Figure 135:South Korea Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032 Figure 136:South Korea Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032 Figure 137:South Korea Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-2032 Figure 138:Australia Molecular Oncology Diagnostics Market, $Million, 2021-2032 17 All rights reserved at BIS Research Inc.

  18. Figure 139:Australia Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021-2032 Figure 140:Australia Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021-2032 Figure 141:Australia Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-2032 Figure 142:Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market, $Million, 2021-2032 Figure 143:Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market (by Cancer Type), $Million, 2021- 2032 Figure 144:Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market (by Solid Tumor), $Million, 2021- 2032 Figure 145:Rest-of-Asia-Pacific Molecular Oncology Diagnostics Market (by Hematological Malignancy), $Million, 2021-2032 Figure 146:Rest-of-the-World Molecular Oncology Diagnostics Market, $Million, 2021-2032 Figure 147:Total Number of Companies Profiled Figure 148:Agilent Technologies, Inc.: Product Portfolio Figure 149:Agilent Technologies, Inc.: Overall Financials, $Million, 2019-2021 Figure 150:Agilent Technologies, Inc.: Revenue (by Segment), $Million, 2019-2021 Figure 151:Agilent Technologies, Inc.: Revenue (by Region), $Million, 2019-2021 Figure 152:Agilent Technologies, Inc: R&D Expenditure, $Million, 2019-2021 Figure 153:Abbott.: Overall Product Portfolio Figure 154:Abbott.: Overall Financials, $Million, 2019-2021 Figure 155:Abbott.: Revenue (by Segment), $Million, 2019-2021 GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET Figure 156:Abbott.: Revenue (by Region), $Million, 2019-2021 Figure 157:Abbott.: R&D Expenditure, $Million, 2019-2021 Figure 158:Biocartis NV.: Product Portfolio Figure 159:Biocartis NV: Overall Financials, $Million, 2019-2021 Figure 160:Bio-Rad Laboratories, Inc.: Product Portfolio Figure 161:Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2019-2021 Figure 162:Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2019-2021 Figure 163:Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2019-2021 Figure 164:Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2019-2021 Figure 165:F. Hoffmann-La Roche Ltd.: Product Portfolio Figure 166:F. Hoffmann-La Roche Ltd.: Overall Financials, $Million, 2019-2021 Figure 167:F. Hoffmann-La Roche Ltd.: Revenue (by Segment), $Million, 2019-2021 18 All rights reserved at BIS Research Inc.

  19. Figure 168:F. Hoffmann-La Roche Ltd.: Revenue (by Region), $Million, 2019-2021 Figure 169:F. Hoffmann-La Roche Ltd.: R&D Expenditure, $Million, 2019-2021 Figure 170:QIAGEN N.V.: Product Portfolio Figure 171:QIAGEN N.V.: Overall Financials, $Million, 2019-2021 Figure 172:QIAGEN N.V.: Revenue (by Segment), $Million, 2019-2021 Figure 173:QIAGEN N.V.: Revenue (by Region), $Million, 2019-2021 Figure 174:QIAGEN N.V.: R&D Expenditure, $Million, 2019-2021 Figure 175:Thermo Fisher Scientific, Inc.: Product Portfolio Figure 176:Thermo Fisher Scientific, Inc.: Overall Financials, $Million, 2019-2021 Figure 177:Thermo Fisher Scientific, Inc.: Revenue (by Segment), $Million, 2019-2021 Figure 178:Thermo Fisher Scientific, Inc.: Revenue (by Region), $Million, 2019-2021 Figure 179:Thermo Fisher Scientific, Inc.: R&D Expenditure, $Million, 2019-2021 Figure 180:Danaher.: Product Portfolio Figure 181:Danaher.: Overall Financials, $Million, 2019-2021 Figure 182:Danaher.: Revenue (by Segment), $Million, 2019-2021 Figure 183:Danaher.: Revenue (by Region), $Million, 2019-2021 Figure 184:Danaher.: R&D Expenditure, $Million, 2019-2021 Figure 185:Guardant Health: Overall Product Portfolio Figure 186:Guardant Health: Overall Financials, $Million, 2019-2021 Figure 187:Guardant Health: Revenue (by Segment), 2019-2021 GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET Figure 188:Guardant Health: R&D Expenditure, $Million, 2019-2021 Figure 189:HTG Molecular Diagnostics, Inc.: Overall Product Portfolio Figure 190:HTG Molecular Diagnostics, Inc.: Overall Financials, $Million, 2019-2021 Figure 191:HTG Molecular Diagnostics, Inc.: Revenue (by Segment), 2019-2021 Figure 192:HTG Molecular Diagnostics, Inc.: R&D Expenditure, $Million, 2019-2021 Figure 193:Illumina, Inc.: Overall Product Portfolio Figure 194:Illumina, Inc.: Overall Financials, $Million, 2019-2021 Figure 195:Illumina, Inc.: Revenue (by Segment), $Million, 2019-2021 Figure 196:Illumina, Inc.: Revenue (by Region), $Million, 2019-2021 Figure 197:Illumina, Inc.: R&D Expenditure, $Million, 2019-2021 Figure 198:Invivoscribe, Inc.: Overall Product Portfolio Figure 199:Myriad Genetics, Inc.: Product Portfolio Figure 200:Myriad Genetics, Inc.: Overall Financials, $Million, 2019-2021 19 All rights reserved at BIS Research Inc.

  20. Figure 201:Myriad Genetics, Inc.: Revenue (by Segment), $Million, 2019-2021 Figure 202:Myriad Genetics, Inc.: R&D Expenditure, $Million, 2019-2021 Figure 203:Sysmex Corporation: Overall Product Portfolio Figure 204:Sysmex Corporation: Overall Financials, $Million, 2019-2021 Figure 205:Sysmex Corporation: Revenue (by Region), $Million, 2019-2021 Figure 206:Sysmex Corporation: R&D Expenditure, $Million, 2019-2021 GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET 20 All rights reserved at BIS Research Inc.

  21. List of Tables Table 1: Biomarkers for Different Cancer Types Table 2: Cost of Liquid Biopsy Based NGS Diagnostic Kits Table 3: Companies Providing Kits and Assays for Molecular Oncology Diagnostics GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET 21 All rights reserved at BIS Research Inc.

  22. BIS Research Offerings: We are on a mission to harness the potential of disruptive technologies to make businesses thrive in today’s digital age. We have a vision to be a leading and a preferred knowledge partner for corporates and institutions worldwide and assist them with market intelligence in the area of emerging technologies, advisories, and other innovative solutions. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET Know More Know More Know More Know More 22 All rights reserved at BIS Research Inc.

  23. Disclaimer BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth. This document and its contents are confidential and may not be further distributed, published or reproduced, in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS Research Inc. Customer will not disclose the contents of the report, whether directly in any media or indirectly through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce Information in legal proceedings. Market reports are based on expectations, estimates and projections as of the date such information is available. Any recommendation contained in this report may not be suitable for all investors or businesses. The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while considered reasonable by BIS Research Inc. as of the date of such statements, are inherently subject to market fluctuations and business, economic and competitive uncertainties and contingencies. For more details regarding permission, please contact us: Email: sales@bisresearch.com Tel: +1 510 404 8135 GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET 23 All rights reserved at BIS Research Inc.

  24. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTIC MARKET BIS RESEARCH INC. 39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686 E-mail: hello@bisresearch.com | Call Us: +1-510-404-8135 Global Delivery Center Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway, Sector 126, Noida, U.P., 201303, India Tel: +91 120 4261540 / 4261544 24 www.bisresearch.com All rights reserved at BIS Research Inc.

More Related